SCLX vs. MKTW, RLAY, OCUL, CGEM, ARQT, IRON, COLL, BCYC, ANAB, and CNTA
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include MarketWise (MKTW), Relay Therapeutics (RLAY), Ocular Therapeutix (OCUL), Cullinan Therapeutics (CGEM), Arcutis Biotherapeutics (ARQT), Disc Medicine (IRON), Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), and Centessa Pharmaceuticals (CNTA).
MarketWise (NASDAQ:MKTW) and Scilex (NASDAQ:SCLX) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
MarketWise has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
MarketWise has higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than MarketWise, indicating that it is currently the more affordable of the two stocks.
23.0% of MarketWise shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 28.6% of MarketWise shares are owned by company insiders. Comparatively, 8.7% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Scilex had 1 more articles in the media than MarketWise. MarketBeat recorded 4 mentions for Scilex and 3 mentions for MarketWise. MarketWise's average media sentiment score of 0.62 beat Scilex's score of 0.30 indicating that Scilex is being referred to more favorably in the news media.
MarketWise received 18 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 65.00% of users gave MarketWise an outperform vote.
MarketWise presently has a consensus target price of $2.50, indicating a potential upside of 117.39%. Scilex has a consensus target price of $8.00, indicating a potential upside of 376.19%. Given MarketWise's stronger consensus rating and higher probable upside, analysts clearly believe Scilex is more favorable than MarketWise.
MarketWise has a net margin of 0.46% compared to MarketWise's net margin of -229.47%. MarketWise's return on equity of 0.00% beat Scilex's return on equity.
Summary
Scilex beats MarketWise on 10 of the 18 factors compared between the two stocks.
Get Scilex News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
